Partner and Managing Director – TPG Life Sciences Innovation
Dr. Shinichiro (Shin) Fuse, is Partner and Managing Director at TPG Life Sciences Innovation. Previously, he was Managing Director at MPM Capital, where he served on the investment committee of the Oncology Impact Fund (OIF) and BioVentures Funds. Shin served on the Board of Directors of Orna Therapeutics, Triplet Therapeutics, iOmx Therapeutics and a stealth company, and as a board observer for Repare Therapeutics and CODA Biotherapeutics. Shin also played operational roles at MPM portfolio companies as the interim CEO of Orna Therapeutics and interim/founding SVP of Business Development at ElevateBio.
Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and genome editing, including the acquisition of Pregenen. Previously, he was at Campbell Alliance (Syneos Health) as a life science strategy consultant, and at PureTech Ventures, where he was a member of the founding team of Vedanta Biosciences. He currently serves on the Board of Advisors of the Guarini School of Graduate and Advanced Studies at Dartmouth College, and also as a columnist for Nikkei Biotech, the leading biotech journal in Japan.
Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.